H. Lee Moffitt Cancer Center And Research Institute

This early-phase trial tested a personalized vaccine made from a patient's own immune cells, designed to recognize and attack HER-2 positive breast cancer cells. The goal was to see if the vaccine is safe and can boost the immune system to prevent the cancer from returning. The s…

This study tested a new treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) when standard drugs stop working. The treatment uses immune cells from a donor that are specially processed to reduce the risk of attacking the patient's bod…

This study tested a smartphone app designed to help people quit smoking. 520 smokers who use food banks participated. The app provided support and tracked progress. The goal was to see if the app could help people stop smoking for good.

This early-phase study tested a combination of the immunotherapy drug avelumab and whole brain radiotherapy in 16 people with leptomeningeal disease, a rare condition where cancer spreads to the lining of the brain and spinal cord. The main goal was to find a safe dose and identi…

This study tested a combination of two immunotherapies—an injected drug (Tavo) plus an IV drug (nivolumab)—in 17 people with advanced melanoma that could be surgically removed. The goal was to see if the treatment could eliminate or shrink tumors before surgery. After treatment, …

This early-phase trial tested a treatment that uses a patient's own immune cells (called TILs) to fight soft tissue sarcoma. Nine young adults received chemotherapy to lower their immune system, then an infusion of their own tumor-fighting cells plus high-dose IL-2. The main goal…

This study tested a combination of two immunotherapy drugs—high-dose interleukin-2 (IL-2) and pembrolizumab (Keytruda)—in 27 people with metastatic kidney cancer. The goal was to see if the pair could shrink tumors better than either drug alone. Participants received both drugs i…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 20 people with advanced neuroendocrine tumors that had worsened despite prior treatments. The goal was to see if the combination could shrink tumors or slow cancer growth. The study measured how many p…

This early-phase study tested a new treatment called TBio-4101 for people with advanced melanoma that has stopped responding to standard therapies. The treatment uses a patient's own immune cells (TILs) that are selected and grown in a lab, then given back after chemotherapy to h…

This early-phase trial tested the safety of adding two drugs—pembrolizumab and vorinostat—to standard chemotherapy and radiation for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study enrolled 21 adults with good overall health. The main goal was to f…

This early-phase trial tested a combination of two drugs, IRX-2 and durvalumab, in 19 people with advanced head and neck cancer that could not be cured with standard treatments. The main goals were to check safety and see if the drugs could boost the immune system's attack on tum…

This study tested a new treatment for advanced melanoma that uses a patient's own immune cells. Doctors removed tumor-infiltrating lymphocytes (TILs) from the patient, grew them in a lab, and then gave them back along with high-dose IL-2 to boost the immune system. The main goal …

This study tested a way to deliver three chemotherapy drugs directly to the tumor through an artery in 34 adults with malignant pleural mesothelioma that could not be removed by surgery. The goal was to see if this approach could control the disease and how safe it was. The treat…

This early-phase study tested whether giving a type of focused radiation (stereotactic radiosurgery) right after an immunotherapy drug (nivolumab) is safe and helps control breast cancer that has spread to the brain. Fourteen adults with up to 10 brain tumors took part. The main …

This study tested the drug nivolumab in 54 people with advanced bile duct or gallbladder cancers that had stopped responding to other treatments. The goal was to see if nivolumab could shrink tumors or slow the cancer. While nivolumab is approved for other cancers, it is not yet …

This study tested whether adding the drug pirfenidone (already approved for a different lung condition) to standard chemotherapy is safe and effective for people with advanced non-small cell lung cancer. 48 participants received the combination. The main goals were to find the be…

This study tested a combination of two chemotherapy drugs (nab-paclitaxel and gemcitabine) in 59 teenagers and young adults whose sarcoma (a type of bone or soft tissue cancer) had returned or was not responding to standard treatment. The goal was to see if the combo could shrink…

This early-phase study tested a combination of two targeted drugs, trametinib and ceritinib, in 27 adults with advanced melanoma that could not be removed by surgery and had stopped responding to standard treatments. The main goals were to find the safest dose and see if the comb…

This study tested a combination of a targeted drug (vemurafenib), special immune cells (T-cells), and high-dose IL-2 in 17 people with advanced melanoma that had spread. The goal was to see if this approach could shrink or control tumors. While the treatment aims to fight the can…

This study tested whether a digital social network assessment tool plus a caregiver navigator could reduce stress and burden for family caregivers of brain cancer patients. About 296 caregivers and patients took part. The program measured anxiety, depression, and overall well-bei…

This study tested a smartphone app that uses augmented reality to help reduce cigarette cravings. 14 adults who had recently quit smoking tried the app and rated how easy it was to use and how much they liked it. The goal was to see if the app could be a helpful tool for quitting…

This study tested whether using a person's DNA to select an antidepressant works better than standard prescribing for cancer patients with depression or anxiety. 99 adults with cancer were randomly assigned to either DNA-guided drug choice or usual care. The researchers compared …

This study looked at whether eating only during an 8-10 hour daytime window (without cutting calories) could help immunotherapy work better in people with advanced head and neck cancer. 29 patients were asked to track their eating times using a phone app. The goal was to see if t…

This study tested a new mindfulness-based program to help people reduce alcohol use and quit smoking. 67 adults who smoked and drank alcohol participated. The program focused on teaching mindfulness skills to manage cravings and support behavior change. The study measured how sat…

This study tested whether a pickleball program is practical and enjoyable for cancer survivors and their family members or friends. The goal was to increase physical activity and improve overall wellness. Researchers measured how many people joined, stuck with the program, and fo…

This study tested a mobile health (mHealth) program designed to help people who have had a blood stem cell transplant sleep better. About 30 survivors with sleep problems took part. The goal was to see if the program was easy to use and if people were satisfied with it.

This study tested a program called STRONG-PD that provides nutrition support from home for people with gastrointestinal cancer that has spread to the lining of the belly. Ten patients who had surgery and chemotherapy tried the program, which included remote guidance from a dietit…

This study tested a smartphone app designed to educate and monitor patients with stage IV kidney cancer who are starting combination immunotherapy. Twenty patients used the app, and researchers measured how acceptable and helpful it was, including its effect on quality of life. T…

This early-phase study tested whether giving a single dose of nivolumab with either ipilimumab or relatlimab before brain surgery is safe and feasible in adults with melanoma that has spread to the brain. Only one person enrolled, so the main goal was to see if recruitment was po…

This study provided educational materials about colorectal cancer and screening recommendations to adults aged 45-75 in the Tampa Bay area. Researchers measured changes in knowledge and screening intentions through surveys at baseline, 3 months, and 6 months. The goal was to see …

This study looked at whether teaching people about clinical trials helps them understand them better. 85 adults from the Tampa Bay area took a survey before and after an educational session. The goal was to see if their knowledge and attitudes about clinical trials improved.

This study looked at whether telling people about their genetic risk for melanoma (a serious skin cancer) changes how well they protect themselves from the sun. Over 2,000 adults took part, and researchers measured things like time in the sun, sunscreen use, and sunburns before a…

This study looked at how men from different racial and ethnic backgrounds think about their genetic risk for prostate cancer. Researchers asked 100 men aged 40 and older who had never had prostate cancer to share their beliefs and provide a saliva sample for genetic testing. The …

This study looked at 30 people with a rare and aggressive type of gut cancer called poorly-differentiated neuroendocrine carcinoma. Researchers used a special PET scan to measure how much of a certain protein (somatostatin receptor) the tumors have. The goal was to see if enough …

This study tested a device called EnVisio SmartClip that helps doctors locate breast tumors during surgery. Fifty people with breast cancer took part. The goal was to see if the device could accurately guide surgeons to the right spot for removal.

This study tested whether a mathematical model could help doctors choose the best radiation schedule for people with HPV-positive throat cancer. The goal was to see if personalized dosing could shrink tumors faster. 55 patients took part, and the approach aimed to improve the num…

This study looked at whether an exercise program is practical for people aged 65 and older with blood cancers like lymphoma, leukemia, or myeloma who are about to receive CAR T-cell therapy. Twenty participants were enrolled to see if they would join, stick with, and safely compl…